Review
Biochemistry & Molecular Biology
Teresa Tan, Suphamai Bunnapradist
Summary: The most commonly used immunosuppressant in organ transplant, tacrolimus, exhibits variability and necessitates routine concentration monitoring. Extended-release tacrolimus tablets (LCP-TAC) may have a more favorable PK profile than immediate-release tacrolimus (IR-TAC). Ongoing studies are evaluating the clinical impact of these PK differences on kidney transplant patients, with larger prospective studies needed to evaluate survival differences.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2021)
Article
Behavioral Sciences
Alice Servonnet, Hiroyuki Uchida, Anne-Noel Samaha
Summary: Continuous exposure to antipsychotic drugs may increase the risk of long-term adverse effects, while regular but extended dosing has been proved to be safer and more effective for patients, reducing overall drug exposure. Studies in laboratory animals show that compared to continuous exposure, regular but extended dosing has superior antipsychotic-like efficacy and substantially reduces the likelihood of motor side effects and dopamine receptor supersensitivity.
BEHAVIOURAL BRAIN RESEARCH
(2021)
Article
Pharmacology & Pharmacy
Sathish Dharani, Eman M. Mohamed, Tahir Khuroo, Hamed I. Ali, Indra K. Reddy, Ziyaur Rahman, Mansoor A. Khan
Summary: The present study aimed to evaluate the in-use stability of commercial metformin products for the carcinogenic impurity NDMA and dissolution quality attributes. The results showed that multiple products exceeded the acceptable daily intake limit for NDMA and the impurity levels significantly increased after stability exposure, indicating that more products in the market may soon be recalled.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Review
Pharmacology & Pharmacy
Sheng Chao, Lei Jia, Kejing Zhu, Luobei Chen, Yulin Niu
Summary: This meta-analysis supports the conversion from immediate-release to extended-release formulation of tacrolimus in improving kidney function to some extent in renal transplant patients, especially for patients with longer follow-up duration.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Clinical Neurology
Robert A. Hauser, Leonid Zeitlin, Stanley Fisher, Richard D'Souza
Summary: In the ADVANCE-PD trial, it was found that CD-LD ER significantly increased ON time per dose compared to CD-LD IR (+1.21 h, p < 0.0001) and provided significantly more ON time per dose (3.55 h vs 2.38 h, p < 0.0001). This suggests that CD-LD ER has an advantage in improving symptoms of patients with Parkinson's disease.
PARKINSONISM & RELATED DISORDERS
(2021)
Article
Pharmacology & Pharmacy
Arnaud Del Bello, Clotilde Gaible, Nathalie Longlune, Anne-Laure Hebral, Laure Esposito, Peggy Gandia, Nassim Kamar
Summary: The study examined the modifications of tacrolimus intra-patient variability (IPV) in solid organ transplant recipients after switching from immediate-release or prolonged-release tacrolimus to extended-release LCP-tacrolimus. The switch was considered safe, with no significant impact on tacrolimus IPV observed.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Toxicology
Daniel A. Spyker, Richard C. Dart, Luke Yip, Kate Reynolds, Scott Brittain, Mark Yarema
Summary: This study examined the pharmacokinetic profiles of acetaminophen overdose and found that delayed release formulations have slower absorption and decreased bioavailability compared to immediate release formulations.
CLINICAL TOXICOLOGY
(2022)
Article
Clinical Neurology
Y. Joseph Hwang, G. Caleb Alexander, Huijun An, Thomas J. Moore, Hemalkumar B. Mehta
Summary: The use of pimavanserin in patients with Parkinson's disease who are 65 or older and residing in Medicare-certified long-term care facilities is associated with an increased risk of 30-day hospitalization and higher 90-, 180-, and 365-day mortality.
Review
Biochemistry & Molecular Biology
Diana Duarte, Nuno Vale
Summary: Drug repurposing is an effective strategy to expedite the discovery of new clinical uses for already approved drugs for different diseases, with fluphenazine showing great potential in cancer therapy.
Article
Multidisciplinary Sciences
Simone Patergnani, Massimo Bonora, Selene Ingusci, Maurizio Previati, Saverio Marchi, Silvia Zucchini, Mariasole Perrone, Mariusz R. Wieckowski, Massimiliano Castellazzi, Maura Pugliatti, Carlotta Giorgi, Michele Simonato, Paolo Pinton
Summary: The study found that autophagy and mitophagy are increased in MS patients, with inhibitors of autophagy improving myelination and behavioral signs in experimental models of the disease, suggesting a causal role of autophagy in MS and potential therapeutic benefits of autophagy inhibitors like haloperidol and clozapine.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Chemistry, Multidisciplinary
Jiahuan You, Changwei Yang, Jinpeng Han, Hao Wang, Wentao Zhang, Ying Zhang, Ziyi Lu, Shiqi Wang, Ruisi Cai, Hongjun Li, Jicheng Yu, Jianqing Gao, Yuqi Zhang, Zhen Gu
Summary: An ultrarapid-acting microneedle (URA-MN) patch is proposed for minimally invasive transdermal delivery of biotherapeutics. By incorporating effervescent agents into the needle tip, accelerated drug release is achieved. Rapid release, easy administration, and excellent biocompatibility of URA-MN are demonstrated in three different mouse models.
ADVANCED MATERIALS
(2023)
Article
Biochemistry & Molecular Biology
Maria Podsiedlik, Magdalena Markowicz-Piasecka, Joanna Sikora
Summary: The aim of this study was to assess the potency of selected antipsychotic drugs on the main pathological hallmarks of Alzheimer's disease. The tested antipsychotics showed inhibition on acetylcholinesterase and Aβ aggregation, and exhibited antioxidant properties in cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Neurosciences
Robert A. Mccutcheon, Paul J. Harrison, Oliver D. Howes, Philip K. Mcguire, David M. Taylor, Toby Pillinger
Summary: This study analyzed the receptor affinities of antipsychotic medications and grouped them into four categories based on their predominant receptor affinities. The classification was shown to predict clinical effects of the drugs and has the potential to guide treatment and inform drug development.
BIOLOGICAL PSYCHIATRY
(2023)
Article
Surgery
Yoonhee P. Ha, Gillian Divard, Nandita Mitra, Mary E. Putt, Nicolas Pallet, Alexandre Loupy, Dany Anglicheau, Jennifer Trofe-Clark, Christophe Legendre, Roy D. Bloom, Peter P. Reese
Summary: This study suggests that extended-release tacrolimus capsules do not reduce the risk of poor outcomes compared to immediate-release tacrolimus capsules in kidney transplant recipients with generally high immunological risks.
CLINICAL TRANSPLANTATION
(2023)
Review
Behavioral Sciences
Barry E. Gidal, Jim Ferry, Larisa Reyderman, Jesus E. Pina-Garza
Summary: Long-acting and long half-life anti-seizure medications have advantages in reducing dosing frequency, simplifying dosing regimens, reducing pill burden, and decreasing fluctuations in serum drug concentration, which may lead to decreased risk of adverse effects and seizures.
EPILEPSY & BEHAVIOR
(2021)
Letter
Clinical Neurology
Itsuki Terao, Mina Honyashiki, Takeshi Inoue
JOURNAL OF PSYCHOPHARMACOLOGY
(2022)
Review
Psychology, Developmental
Itsuki Terao, Wakako Kodama, Haruka Tsuda
Summary: This study conducted a dose-response meta-analysis to estimate the relationship between the dose of atomoxetine and its effectiveness in treating children with ADHD. The analysis included 12 double-blind randomized placebo-controlled trials and found that the efficacy of atomoxetine reached its maximum at a dosage of 1.4 mg/kg, after which it plateaued.
JOURNAL OF ATTENTION DISORDERS
(2023)